Snowball logo
logo
0419

Komipharm International Co. Ltd

041960 β€’ KQ
β‚©9,150.00+β‚©120.00Β  (1.33%)
πŸ’‘ Click on a row in the table to make it appear on the graph
πŸ“Š Compare financials of multiple companies on the same chart
This feature is available with our premium plans. Upgrade to unlock the full potential of Snowball Analytics and be on top of your investments!
20212022202320242025TTM
Revenue
Total revenue
35,847.439,800.542,64758,778.552,465.349,993.5
COGS
24,613.228,341.729,988.937,014.535,406.333,079
Gross Profit
11,234.311,458.812,658.221,76417,058.916,914.5
Operating Expenses & Income
Operating Income
(5,641.9)(3,990)(6,371.1)4,957.41,960.51,752.2
Total Operating Expenses
41,138.143,604.348,920.152,585.650,504.848,241.3
R&D Expenses
5,117.42,535.85,9452,465.91,629.91,500
Selling General & Admin Expenses
9,750.410,81511,311.711,773.95,099.25,096.5
Earnings from Continuing Operations
Interest Expense
(1,656.5)(2,216.1)(2,551.9)(3,205.9)(2,598.6)(2,295.7)
Interest Income
391.13,505.3471.6181.7834.8815.6
Income Tax Expense
------
Net Income
Net Income
(4,459.4)(6,513.8)(3,979.1)13,113.3(7,208.7)(6,398.3)
Supplemental
EBIT
(5,290.7)-----
EBITDA
------
In millions of KRW, except % and values per 1 share